Madhu Kumar
Stock Analyst at Goldman Sachs
(2.88)
# 1,574
Out of 5,131 analysts
145
Total ratings
56.44%
Success rate
20.36%
Average return
Main Sectors:
Stocks Rated by Madhu Kumar
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| JAZZ Jazz Pharmaceuticals | Maintains: Buy | $162 → $185 | $161.13 | +14.81% | 8 | Aug 29, 2025 | |
| FULC Fulcrum Therapeutics | Maintains: Neutral | $5 → $6 | $9.85 | -39.09% | 8 | Jan 26, 2024 | |
| UTZ Utz Brands | Maintains: Neutral | $19 → $17 | $9.94 | +71.03% | 2 | Nov 10, 2023 | |
| ALEC Alector | Initiates: Sell | $4 | $1.86 | +115.05% | 4 | Sep 25, 2023 | |
| KRYS Krystal Biotech | Maintains: Buy | $135 → $155 | $261.41 | -40.71% | 13 | May 22, 2023 | |
| CYTK Cytokinetics | Maintains: Buy | $48 → $53 | $62.51 | -15.21% | 4 | May 5, 2023 | |
| DSGN Design Therapeutics | Upgrades: Neutral | n/a | $9.39 | - | 3 | May 4, 2023 | |
| ARWR Arrowhead Pharmaceuticals | Maintains: Buy | $65 → $73 | $64.56 | +13.07% | 10 | May 3, 2023 | |
| APLS Apellis Pharmaceuticals | Maintains: Buy | $124 → $141 | $27.30 | +416.48% | 9 | Apr 14, 2023 | |
| SNDX Syndax Pharmaceuticals | Maintains: Buy | $39 → $34 | $21.00 | +61.90% | 6 | Mar 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $20 → $6 | $2.45 | +144.90% | 8 | Dec 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sell | $8 → $14 | $6.78 | +106.49% | 6 | Nov 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $24 → $21 | $15.41 | +36.28% | 2 | Nov 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | $5 | $24.90 | -79.92% | 3 | Aug 25, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sell | $10 → $8 | $2.07 | +286.47% | 4 | May 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $111 → $89 | $12.07 | +637.37% | 4 | May 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $580 → $120 | $19.85 | +504.53% | 1 | Jan 19, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | $10 | $0.10 | +9,840.36% | 1 | Aug 27, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $60 → $85 | $10.38 | +718.88% | 7 | Jun 23, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $23 → $39 | $4.41 | +784.35% | 3 | Mar 16, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $58 → $57 | $25.32 | +125.12% | 3 | Jul 31, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $4.62 | - | 15 | Jul 24, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $900 | $0.95 | +95,117.94% | 1 | Apr 21, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underperform | $17 → $20 | $5.85 | +241.88% | 2 | Mar 27, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $140 → $100 | $0.28 | +35,398.76% | 5 | Mar 13, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $35 | $42.18 | -17.02% | 1 | Mar 12, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $58 → $40 | $16.23 | +146.46% | 2 | Sep 24, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $504 | $31.74 | +1,487.90% | 3 | Oct 8, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $210 → $230 | $398.29 | -42.25% | 2 | Aug 13, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $150 → $1,125 | $10.79 | +10,326.32% | 2 | Feb 9, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $40 | $1.04 | +3,746.15% | 1 | Feb 8, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Buy | $22 | $28.47 | -24.48% | 1 | Dec 1, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $24 | $53.84 | -56.35% | 1 | Mar 28, 2017 |
Jazz Pharmaceuticals
Aug 29, 2025
Maintains: Buy
Price Target: $162 → $185
Current: $161.13
Upside: +14.81%
Fulcrum Therapeutics
Jan 26, 2024
Maintains: Neutral
Price Target: $5 → $6
Current: $9.85
Upside: -39.09%
Utz Brands
Nov 10, 2023
Maintains: Neutral
Price Target: $19 → $17
Current: $9.94
Upside: +71.03%
Alector
Sep 25, 2023
Initiates: Sell
Price Target: $4
Current: $1.86
Upside: +115.05%
Krystal Biotech
May 22, 2023
Maintains: Buy
Price Target: $135 → $155
Current: $261.41
Upside: -40.71%
Cytokinetics
May 5, 2023
Maintains: Buy
Price Target: $48 → $53
Current: $62.51
Upside: -15.21%
Design Therapeutics
May 4, 2023
Upgrades: Neutral
Price Target: n/a
Current: $9.39
Upside: -
Arrowhead Pharmaceuticals
May 3, 2023
Maintains: Buy
Price Target: $65 → $73
Current: $64.56
Upside: +13.07%
Apellis Pharmaceuticals
Apr 14, 2023
Maintains: Buy
Price Target: $124 → $141
Current: $27.30
Upside: +416.48%
Syndax Pharmaceuticals
Mar 1, 2023
Maintains: Buy
Price Target: $39 → $34
Current: $21.00
Upside: +61.90%
Dec 9, 2022
Downgrades: Neutral
Price Target: $20 → $6
Current: $2.45
Upside: +144.90%
Nov 10, 2022
Maintains: Sell
Price Target: $8 → $14
Current: $6.78
Upside: +106.49%
Nov 4, 2022
Maintains: Buy
Price Target: $24 → $21
Current: $15.41
Upside: +36.28%
Aug 25, 2022
Downgrades: Sell
Price Target: $5
Current: $24.90
Upside: -79.92%
May 24, 2022
Maintains: Sell
Price Target: $10 → $8
Current: $2.07
Upside: +286.47%
May 24, 2022
Maintains: Buy
Price Target: $111 → $89
Current: $12.07
Upside: +637.37%
Jan 19, 2022
Downgrades: Neutral
Price Target: $580 → $120
Current: $19.85
Upside: +504.53%
Aug 27, 2021
Downgrades: Sell
Price Target: $10
Current: $0.10
Upside: +9,840.36%
Jun 23, 2021
Maintains: Neutral
Price Target: $60 → $85
Current: $10.38
Upside: +718.88%
Mar 16, 2021
Upgrades: Outperform
Price Target: $23 → $39
Current: $4.41
Upside: +784.35%
Jul 31, 2020
Upgrades: Outperform
Price Target: $58 → $57
Current: $25.32
Upside: +125.12%
Jul 24, 2020
Downgrades: Neutral
Price Target: n/a
Current: $4.62
Upside: -
Apr 21, 2020
Initiates: Outperform
Price Target: $900
Current: $0.95
Upside: +95,117.94%
Mar 27, 2020
Maintains: Underperform
Price Target: $17 → $20
Current: $5.85
Upside: +241.88%
Mar 13, 2020
Maintains: Buy
Price Target: $140 → $100
Current: $0.28
Upside: +35,398.76%
Mar 12, 2020
Initiates: Outperform
Price Target: $35
Current: $42.18
Upside: -17.02%
Sep 24, 2019
Maintains: Buy
Price Target: $58 → $40
Current: $16.23
Upside: +146.46%
Oct 8, 2018
Upgrades: Buy
Price Target: $504
Current: $31.74
Upside: +1,487.90%
Aug 13, 2018
Maintains: Buy
Price Target: $210 → $230
Current: $398.29
Upside: -42.25%
Feb 9, 2018
Maintains: Buy
Price Target: $150 → $1,125
Current: $10.79
Upside: +10,326.32%
Feb 8, 2018
Initiates: Buy
Price Target: $40
Current: $1.04
Upside: +3,746.15%
Dec 1, 2017
Reinstates: Buy
Price Target: $22
Current: $28.47
Upside: -24.48%
Mar 28, 2017
Initiates: Buy
Price Target: $24
Current: $53.84
Upside: -56.35%